The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
Tarih
2019Yazar
Onal, Cem
Sedef, Ali Murat
Kose, Fatih
Oymak, Ezgi
Guler, Ozan Cem
Sumbul, Ahmet Taner
Aksoy, Sercan
Yildirim, Berna Akkus
Besen, Ali Ayberk
Muallaoglu, Sadik
Mertsoylu, Huseyin
Ozyigit, Gokhan
Üst veri
Tüm öğe kaydını gösterÖzet
Currently, there are no predictive markers of response to abiraterone. We calculated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at baseline and at 4 and 12 weeks after initiation of abiraterone, and we evaluated prostate-specific antigen (PSA) response every 4 weeks in 102 metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone either pre-or postchemotherapy. With a median follow-up was 24.0 months (range: 0.3-54.9), median overall survival (OS) was 20.8 months. High-NLR patients who remained high or who returned to low NLR after 4 and 12 weeks showed significantly worse OS than patients with low baseline NLR. NLR and prostate-specific antigen response to abiraterone was a significant predictor of OS and progression-free survival (PFS) in metastatic castration-resistant prostate cancer patients treated with abiraterone delivered either pre-or postchemotherapy.